Nine Chapters Capital Management’s Charles River Laboratories CRL Stock Holding History

Nine Chapters Capital Management’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-25,900	Closed	-$1.65M	–	135
2015 Q3	$1.65M	Sell	25,900 -6,000	-19%	-$431K	0.14%	197
2015 Q2	$2.24M	Buy	31,900 +16,400	+106%	+$1.21M	0.19%	140
2015 Q1	$1.23M	Sell	15,500 -1,000	-6%	-$73.8K	0.1%	304
2014 Q4	$1.05M	Sell	16,500 -17,300	-51%	-$1.08M	0.09%	314
2014 Q3	$2.02M	Sell	33,800 -31,200	-48%	-$1.79M	0.18%	155
2014 Q2	$3.48M	Buy	65,000 +53,300	+456%	+$2.92M	0.28%	85
2014 Q1	$706K	Sell	11,700 -27,700	-70%	-$1.61M	0.08%	362
2013 Q4	$2.09M	Sell	39,400 -8,200	-17%	-$412K	0.21%	131
2013 Q3	$2.2M	Buy	47,600 +1,800	+4%	+$82.6K	0.26%	109
2013 Q2	$1.88M	Buy	+45,800	New	+$1.96M	0.32%	76

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Nine Chapters Capital Management's CRL Position: Q4 2015 in Review

Nine Chapters Capital Management sold out of Charles River Laboratories (CRL) in Q4 2015, closing a stake of 25,900 shares — an estimated $1.65M sold.

Nine Chapters Capital Management first reported a position in CRL in Q2 2013 and held it in 10 quarters. The position peaked at $3.48M in Q2 2014. 268 funds tracked by Wall St. Rank hold CRL as of Q4 2015.

Nine Chapters Capital Management reported no remaining Charles River Laboratories position as of Q4 2015 after selling out during the quarter.
Nine Chapters Capital Management sold 25,900 Charles River Laboratories shares in Q4 2015, an estimated $1.65M.
Nine Chapters Capital Management first reported a position in Charles River Laboratories in Q2 2013 and held it in 10 quarters.
Nine Chapters Capital Management's Charles River Laboratories position peaked at $3.48M in Q2 2014.
268 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2015.

Based on Nine Chapters Capital Management's 13F filing for Q4 2015.